Cystic fibrosis transmembrane conductance regulator dysfunction is associated with worsened airway disease in patients with COPD.
Total serum bilirubin levels of 9 to 11.9 mg/dL, 12 to 14.9 mg/dL, and 15 to 17.9 mg/dL were associated with significantly greater risks for asthma in infants.
Rivaroxaban was associated with lower clinical event costs but higher total healthcare costs compared with aspirin in patients with venous thromboembolism.
No difference in mortality, but there may be an elevated risk for suicide with long-term benzodiazepine use in patients with COPD and comorbid PTSD.
Middle-aged testosterone replacement therapy users with COPD had a greater reduction in hospitalizations compared with nonusers.
The FDA has granted Orphan Drug Designation to a novel inhaled treatment that could potentially improve lung function in patients with cystic fibrosis.
The risk for obstructive lung disease was nearly 8 times greater in heavy stable smokers compared with never-smokers.
Children with asthma had a 66% higher risk for incident obesity compared with children without asthma.
Bronchial thermoplasty reduced gas trapping in individuals with asthma, particularly in patients with severe disease.
Early pulmonary rehabilitation after hospitalization for an acute exacerbation of COPD was an effective intervention for reducing mortality.
The FDA has approved updated labeling for Stiolto Respimat to include COPD exacerbation data and a revised indication.
Patients who received a discharge care bundle after being hospitalized for an acute exacerbation of COPD had a lower rate of readmission.
Infants who presented with pulmonary symptoms when diagnosed with gastroesophageal reflux disease had a higher incidence of early onset asthma compared with infants who did not have pulmonary symptoms.
Patients with chronic obstructive pulmonary disease who used opioids were more likely to be intubated during their hospitalization compared with nonopioid users
Adolescents with asthma treated with dupilumab experienced significant improvements in FEV1 compared with placebo.
Patients with moderate to severe persistent allergic asthma who were treated with omalizumab experienced greater improvements in lung function after 16 weeks compared with those treated with placebo.
Benralizumab was associated with a significant reduction in annual asthma exacerbation rates.
There was a trend toward a reduction in mortality in patients with COPD who received beta-blocker treatment compared with patients who did not.
Montelukast plus levocetirizine demonstrated a significant reduction in mean daytime nasal symptom scores compared with montelukast monotherapy.
Disrupting regular combination inhaled corticosteroid therapy refills increased hospitalizations and exacerbations.